FDA
-
-
-
-
-
-
-
Incannex advances sleep apnea drug with new phase 2 study
-
-
-
-
-
-
-
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026
-
-
-
-
-
-
-
Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X
-
-
-
-
-
-
-
Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
-
-
-
-
-
-
-
Incannex Healthcare (IXHL) Appoints Lou Barbato as Chief Medical Officer
-
-
-
-
-
-
-
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
-
-
-
-
-
-
-
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
-
322,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

